TDF and Entekavir - Hepatitis B Reactivation

Efficacy of TDF and Entekavir Prophylaxis at Hepatitis B Reactivation: Multi Center Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06049602

Enrollment

10000

Registered

2023-09-22

Start date

2023-01-15

Completion date

2023-12-31

Last updated

2023-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B Reactivation

Brief summary

This is a non-interventional retrospective multi-center study for the patients received Entekavir or TDF for Hepatitis B prophylaxis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients used entekavir or TDF for Hepatitis B prophylaxis

Exclusion criteria

* Patients lower then 18 years old.

Design outcomes

Primary

Measure	Time frame	Description
Reactivation Rate	12 months	Percentage of patients reactivated during the Entekavir or TDF

Countries

Turkey (Türkiye)

Contacts

Primary ContactFehmi Tabak, Prof

fehmitabak@yahoo.com+905322763788

Backup ContactIlker Kurkcu

ilker.kurkcu@sentez-cro.com+905326354515

Outcome results